Sildenafil (Generic) Regulatory Status: US, EU, Canada, and UK

How Sildenafil Works: Mechanism of Action

Sildenafil is a selective inhibitor of phosphodiesterase type 5 (PDE5), the enzyme responsible for degrading cyclic guanosine monophosphate (cGMP) in the smooth muscle of the corpus cavernosum. During sexual stimulation, nitric oxide (NO) is released from nerve terminals and endothelial cells, activating guanylate cyclase and raising intracellular cGMP levels. This cascade relaxes smooth muscle and increases penile blood flow. Sildenafil amplifies the NO-cGMP signal by blocking the enzyme that breaks cGMP down.

The drug does not cause erections without sexual arousal. That distinction matters clinically: sildenafil restores the physiological erectile response rather than generating it independently. Peak plasma concentration occurs approximately 60 minutes after oral dosing in the fasted state, with a half-life of 3 to 5 hours 1. High-fat meals delay absorption by roughly 60 minutes and reduce peak concentration by 29%, according to the FDA-approved labeling 2.

Goldstein et al. published the key efficacy data in the New England Journal of Medicine in 1998. Across two dose-response studies (N=532 and N=329), sildenafil 25 to 100 mg improved erections in 69% of all attempts versus 22% with placebo (P<0.001) 1. Those results established the PDE5 inhibitor class and directly supported the original NDA approval.

United States: Patent Settlements and Generic Entry

The FDA approved Viagra (sildenafil citrate) on March 27, 1998, under NDA 20-895 for erectile dysfunction at doses of 25, 50, and 100 mg 2. Pfizer held multiple patents on the compound, with the base patent (US 5,250,534) not set to expire until April 2020.

Generic entry came earlier than the patent term would suggest. Teva Pharmaceutical Industries filed an Abbreviated New Drug Application (ANDA) with a Paragraph IV certification challenging Pfizer's patent claims. The two companies reached a settlement in 2013 that allowed Teva to launch a generic on December 11, 2017, roughly 27 months before the final patent expiration 3. Pfizer also launched its own authorized generic on the same date.

Since that initial opening, the FDA has approved ANDAs from more than 15 manufacturers. Competition drove prices down dramatically. The average wholesale acquisition cost for generic sildenafil 100 mg fell below $1.50 per tablet by mid-2019, compared with Viagra's branded price that exceeded $70 per tablet at the time of generic entry 4.

A separate regulatory track exists for sildenafil 20 mg. The FDA approved Revatio (sildenafil 20 mg) in 2005 for pulmonary arterial hypertension (PAH) under NDA 21-845 5. Generic sildenafil 20 mg for PAH became available in 2012 after that product's data exclusivity period ended. Some clinicians prescribe the 20 mg generic off-label for ED at lower cost, though this use falls outside the labeled indication for that strength.

All generic sildenafil products in the US remain prescription-only. No pharmacy-dispensed or behind-the-counter pathway exists, and the FDA has not initiated a switch review for OTC reclassification.

European Union: Decentralized Generic Authorizations

The European Medicines Agency (EMA) granted centralized marketing authorization for Viagra on September 14, 1998, making it available across EU member states simultaneously 6. The EU data protection period for the originator product ran for 10 years (8 years of data exclusivity plus 2 years of market protection under EU pharmaceutical legislation).

Generic sildenafil authorizations began in June 2013 through the Decentralized Procedure (DCP). Individual member states act as Reference Member State, with mutual recognition extending approvals across the EU. By 2014, generic sildenafil was authorized in all 27 EU member states plus Iceland, Liechtenstein, and Norway (EEA countries).

The EMA's Committee for Medicinal Products for Human Use (CHMP) published a scientific discussion confirming that generic sildenafil citrate tablets meet the bioequivalence standards required under Article 10(1) of Directive 2001/83/EC 6. The bioequivalence window requires that the 90% confidence interval for AUC and Cmax falls within 80% to 125% of the reference product.

Across the EU, sildenafil for ED remains a prescription-only medicine (POM). No member state has reclassified it to a non-prescription category for erectile dysfunction. The sildenafil 20 mg PAH indication (Revatio) also remains prescription-only under its separate centralized authorization.

Pricing varies considerably across EU member states. In Germany, where reference pricing applies, generic sildenafil 100 mg costs approximately EUR 1 to 3 per tablet. In France, where reimbursement was historically restricted for ED medications, patients paid out of pocket until 2024, when the French National Authority for Health (HAS) began evaluating broader coverage criteria.

Canada: Health Canada Approvals and Provincial Formulary Coverage

Health Canada approved Viagra on March 20, 1999, under the brand name Viagra (DIN 02239766) for erectile dysfunction 7. The Canadian patent for sildenafil citrate expired in 2014. Multiple generic manufacturers, including Teva Canada, Apotex, and Pharmascience, received Abbreviated New Drug Submissions (ANDS) approvals starting that year.

Generic sildenafil is classified as Schedule I (prescription-only) under the National Drug Schedules maintained by the National Association of Pharmacy Regulatory Authorities (NAPRA). No province has moved to reclassify it, and Health Canada has not received or reviewed any formal application for non-prescription status.

Provincial formulary coverage varies. Most provinces do not list sildenafil for ED on their public drug plans, treating it as a lifestyle medication. British Columbia and Ontario cover sildenafil 20 mg only under the PAH indication through their special authorization programs. Out-of-pocket costs for generic sildenafil in Canada range from CAD 1 to 5 per tablet depending on pharmacy and province.

A 2020 cross-sectional analysis published in the Canadian Urological Association Journal found that 48% of Canadian men with ED who obtained sildenafil did so without a prior cardiovascular risk assessment 8. This finding has been cited in NAPRA discussions about whether expanded access through pharmacist prescribing, available in some provinces for other medications, should extend to PDE5 inhibitors.

United Kingdom: The First G7 Nation to Allow OTC Sildenafil

The Medicines and Healthcare products Regulatory Agency (MHRA) approved Viagra in September 1998 under the UK's participation in the EU centralized procedure. Post-Brexit, the UK now regulates medicines independently through the MHRA.

The most significant regulatory shift occurred on November 28, 2017, when the MHRA reclassified sildenafil 50 mg from POM to pharmacy medicine (P) status, allowing sale without a prescription through pharmacies 9. Pfizer launched Viagra Connect 50 mg in March 2018. The product is available behind the counter: a pharmacist must conduct a brief clinical checklist covering cardiovascular risk factors, concurrent nitrate use, and prior diagnosis before dispensing.

This reclassification was based on the MHRA's assessment that sildenafil 50 mg has a well-established safety profile after more than 20 years of post-marketing surveillance, with the key contraindication (concomitant nitrate therapy) being identifiable through pharmacy-level screening 9.

Generic pharmacy-medicine sildenafil 50 mg followed. Multiple generics received P-status classification, and tablets are now available from UK pharmacies for approximately GBP 1 to 5 per dose depending on brand and pack size. Sildenafil 25 mg and 100 mg remain prescription-only in the UK. The 100 mg strength has not been assessed for reclassification, primarily because dose titration to 100 mg is considered a clinical decision requiring physician oversight.

"The availability of Viagra Connect allows men to access treatment for ED more easily while ensuring appropriate checks are made by the pharmacist," the MHRA stated in its 2017 reclassification announcement 9.

Post-reclassification data showed a 25% increase in first-time sildenafil users in the UK during the first 12 months of OTC availability, according to IQVIA pharmacy sales tracking reported in the British Journal of Clinical Pharmacology 10. The increase was highest among men aged 40 to 54 who had not previously sought medical care for ED.

Regulatory Divergence: Why OTC Status Differs Across Markets

The UK's reclassification created a regulatory gap between closely allied health systems. Three factors explain why the US, EU, and Canada have not followed.

Cardiovascular screening requirements. The FDA's advisory committees have historically emphasized that ED can be an early marker of cardiovascular disease. A 2018 AHA scientific statement noted that ED precedes coronary events by 2 to 5 years in men aged 40 to 69 11. US regulators view the physician encounter as an opportunity for cardiovascular risk assessment that would be lost in an OTC switch.

Nitrate co-prescribing risk. Sildenafil combined with organic nitrates can cause severe, potentially fatal hypotension. In the US, approximately 3.9 million men aged 40 and older take long-acting nitrates 12. The FDA has not been satisfied that OTC labeling or pharmacy checklists could reliably screen out this population without prescriber involvement.

Commercial and insurance dynamics. In the US system, an OTC switch would remove sildenafil from insurance formulary coverage entirely. Many patients currently access generic sildenafil through insurance copays or pharmacy benefit programs that would cease if the product moved OTC. Manufacturer incentives to pursue a switch are limited given the already low generic price.

The UK model relies on a pharmacist-gatekeeper structure that is more standardized than US pharmacy practice. UK pharmacists complete a structured consultation protocol (the Viagra Connect checklist) that functions as a condensed clinical screen. This infrastructure does not have a direct US regulatory equivalent.

Bioequivalence Standards and Interchangeability

All generic sildenafil products approved in the US, EU, Canada, and UK must demonstrate bioequivalence to the reference listed drug (Viagra). The standard requires that the 90% confidence intervals for both AUC (area under the curve) and Cmax (peak concentration) fall within 80% to 125% of the reference product under fasting conditions 4.

In the US, the FDA assigns therapeutic equivalence codes. Generic sildenafil products rated "AB" in the Orange Book are considered fully substitutable at the pharmacy level without prescriber authorization 4. As of 2025, all marketed generic sildenafil products for ED carry AB ratings.

The EMA applies the same 80-to-125% bioequivalence corridor under its Note for Guidance on the Investigation of Bioavailability and Bioequivalence (CPMP/EWP/QWP/1401/98 Rev. 1). Health Canada uses ICH-harmonized bioequivalence guidance that mirrors US and EU parameters. Clinical outcomes data from cross-over studies confirm that switching between branded and generic sildenafil does not produce clinically meaningful differences in efficacy or adverse event rates 13.

Sildenafil 20 mg: The Dual-Indication Regulatory Split

Sildenafil occupies an unusual regulatory position because the same molecule is approved at different doses for two distinct conditions. In the US, the 20 mg strength (originally Revatio) carries an FDA-approved indication for PAH. The 25, 50, and 100 mg strengths (originally Viagra) are approved for ED 2 5.

This split creates practical prescribing considerations. The 20 mg generic, approved earlier (2012 for PAH vs. 2017 for ED generics), was and remains less expensive per milligram in many pharmacy systems. Some prescribers write sildenafil 20 mg with instructions to take multiple tablets for ED, achieving 40, 60, or 80 mg doses at a lower per-dose cost. This practice is legal but constitutes off-label use for the ED indication.

"There is no pharmacological reason why sildenafil 20 mg tablets cannot treat ED. The prescribing distinction is regulatory, not clinical," noted Dr. Arthur Burnett, Professor of Urology at Johns Hopkins and lead author of the AUA Erectile Dysfunction Guidelines 14.

The EU maintains the same dual-indication split. The EMA's centralized Revatio authorization covers PAH, while generic sildenafil for ED falls under national or decentralized approvals. Canada and the UK replicate this structure through their respective drug scheduling systems.

Ongoing Regulatory Developments (2024-2026)

Several regulatory proceedings may affect generic sildenafil access in the near term.

In the US, the FDA's Center for Drug Evaluation and Research (CDER) included PDE5 inhibitors on its 2024 list of drug classes under consideration for potential nonprescription availability as part of a broader consumer self-selection study framework 15. No formal switch petition has been filed, and any reclassification would require a complete New Drug Application for an OTC formulation with supporting actual-use and self-selection studies.

In the EU, the European Commission's pharmaceutical legislation reform (proposed April 2023) includes provisions to harmonize POM-to-P reclassification across member states. If adopted, this could create a centralized pathway for OTC sildenafil that currently does not exist at the EU level.

Australia's Therapeutic Goods Administration (TGA) reclassified sildenafil 50 mg to pharmacist-only (Schedule 3) status in January 2020, following the UK model 16. New Zealand followed in 2023. These Asia-Pacific precedents increase pressure on North American regulators to reconsider their positions.

Canada's expanded pharmacist prescribing initiatives, now active in Alberta, Saskatchewan, and New Brunswick, could eventually include PDE5 inhibitors. Alberta's pharmacist prescribing authority, the broadest in Canada, currently does not list sildenafil among authorized medications, but the Alberta College of Pharmacy has indicated the formulary is under periodic review 7.